Growth Metrics

Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2017 - 2025)

Alnylam Pharmaceuticals' Change in Acquisitions & Divestments history spans 17 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 100.26% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $59.8 million, up 3.28%, while the annual FY2025 figure was $59.8 million, 3.28% up from the prior year.
  • Change in Acquisitions & Divestments reached $1.7 million in Q3 2025 per ALNY's latest filing, down from $9.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $765.3 million in Q2 2021 to a low of -$647.3 million in Q3 2024.
  • Average Change in Acquisitions & Divestments over 5 years is $242.0 million, with a median of $315.6 million recorded in 2021.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 4643.85% in 2022, then plummeted 98.53% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $291.4 million in 2021, then skyrocketed by 107.49% to $604.7 million in 2022, then tumbled by 98.47% to $9.2 million in 2023, then crashed by 7097.43% to -$647.3 million in 2024, then soared by 100.26% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Change in Acquisitions & Divestments are $1.7 million (Q3 2025), $9.2 million (Q2 2025), and $48.8 million (Q1 2025).